Lee Ainslie Supernus Pharmaceuticals, Inc. Transaction History

Maverick Capital LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$29.91 - $38.73 $29,820 - $38,613	-997 Reduced 11.86%	7,409 $222,000
Q1 2023 May 15, 2023	BUY	$34.93 - $42.03 $24,276 - $29,210	695 Added 9.01%	8,406 $304,000
Q4 2022 Feb 14, 2023	SELL	$31.09 - $37.88 $36,530 - $44,509	-1,175 Reduced 13.22%	7,711 $275,000
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $255,827 - $314,653	8,886 New	8,886 $301,000
Q1 2022 May 16, 2022	SELL	$28.51 - $32.9 $114,040 - $131,600	-4,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$26.37 - $34.22 $1 Million - $1.3 Million	-37,962 Reduced 90.47%	4,000 $117,000
Q3 2021 Nov 15, 2021	SELL	$23.54 - $31.39 $359,903 - $479,921	-15,289 Reduced 26.71%	41,962 $1.12 Million
Q2 2021 Aug 16, 2021	BUY	$26.72 - $33.19 $1.53 Million - $1.9 Million	57,251 New	57,251 $1.76 Million
Q1 2021 May 17, 2021	SELL	$24.15 - $31.45 $41,320 - $53,810	-1,711 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $1.14 Million - $1.66 Million	-64,466 Reduced 97.41%	1,711 $43,000
Q3 2020 Nov 16, 2020	BUY	$20.2 - $25.05 $1.34 Million - $1.66 Million	66,177 New	66,177 $1.38 Million

283

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.11B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.